APO Research
Talk to an analyst

APO RESEARCH · REPORT

Atypical Hemolytic Uremic Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Atypical Hemolytic Uremic Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025184 pages

Choose your research edition.

Industry ResearchAtypical Hemolytic Uremic Syndrome Drug Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Atypical Hemolytic Uremic Syndrome Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Atypical Hemolytic Uremic Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Atypical Hemolytic Uremic Syndrome Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Atypical Hemolytic Uremic Syndrome Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Atypical Hemolytic Uremic Syndrome Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Atypical Hemolytic Uremic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Atypical Hemolytic Uremic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Atypical Hemolytic Uremic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Atypical Hemolytic Uremic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Atypical Hemolytic Uremic Syndrome Drug include Amgen Inc, Omeros Corp, Kedrion SpA, greenovation Biotech GmbH, ChemoCentryx Inc, Alexion Pharmaceuticals Inc, Akari Therapeutics Plc and Achillion Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Atypical Hemolytic Uremic Syndrome Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Atypical Hemolytic Uremic Syndrome Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Atypical Hemolytic Uremic Syndrome Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Atypical Hemolytic Uremic Syndrome Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Atypical Hemolytic Uremic Syndrome Drug Segment by Company

Amgen Inc

Omeros Corp

Kedrion SpA

greenovation Biotech GmbH

ChemoCentryx Inc

Alexion Pharmaceuticals Inc

Akari Therapeutics Plc

Achillion Pharmaceuticals Inc

Atypical Hemolytic Uremic Syndrome Drug Segment by Type

OMS-72

Mubodina

ETR-001

ET-006

CCX-168

ALN-CC5

Others

Atypical Hemolytic Uremic Syndrome Drug Segment by Application

Clinic

Hospital

Others

Atypical Hemolytic Uremic Syndrome Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atypical Hemolytic Uremic Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Atypical Hemolytic Uremic Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atypical Hemolytic Uremic Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Atypical Hemolytic Uremic Syndrome Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Atypical Hemolytic Uremic Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Atypical Hemolytic Uremic Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Atypical Hemolytic Uremic Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Atypical Hemolytic Uremic Syndrome Drug Industry Trends Table 2. Atypical Hemolytic Uremic Syndrome Drug Industry Drivers Table 3. Atypical Hemolytic Uremic Syndrome Drug Industry Opportunities and Challenges Table 4. Atypical Hemolytic Uremic Syndrome Drug Industry Restraints Table 5. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Manufacturers Table 9. Global Atypical Hemolytic Uremic Syndrome Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Atypical Hemolytic Uremic Syndrome Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Atypical Hemolytic Uremic Syndrome Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers, Product Type & Application Table 13. Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Atypical Hemolytic Uremic Syndrome Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of OMS-72 Table 17. Major Manufacturers of Mubodina Table 18. Major Manufacturers of ETR-001 Table 19. Major Manufacturers of ET-006 Table 20. Major Manufacturers of CCX-168 Table 21. Major Manufacturers of ALN-CC5 Table 22. Major Manufacturers of Others Table 23. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2026) & (k units) Table 25. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2027-2032) & (k units) Table 26. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2021-2026) Table 27. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2027-2032) Table 28. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 29. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2026) & (k units) Table 30. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2027-2032) & (k units) Table 31. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2021-2026) Table 32. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Hospital Table 35. Major Manufacturers of Others Table 36. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2026) & (k units) Table 38. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2027-2032) & (k units) Table 39. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2021-2026) Table 40. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2027-2032) Table 41. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 42. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2026) & (k units) Table 43. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2027-2032) & (k units) Table 44. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2021-2026) Table 45. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2027-2032) Table 46. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2021-2026) & (k units) Table 48. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2021-2026) Table 49. Global Atypical Hemolytic Uremic Syndrome Drug Sales Forecasted by Region (2027-2032) & (k units) Table 50. Global Atypical Hemolytic Uremic Syndrome Drug Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 53. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 54. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 56. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 57. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 59. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 60. South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 61. South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 62. South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 63. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2021-2026) Table 67. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2027-2032) Table 68. Amgen Inc Company Information Table 69. Amgen Inc Business Overview Table 70. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 72. Amgen Inc Recent Development Table 73. Omeros Corp Company Information Table 74. Omeros Corp Business Overview Table 75. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 77. Omeros Corp Recent Development Table 78. Kedrion SpA Company Information Table 79. Kedrion SpA Business Overview Table 80. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 82. Kedrion SpA Recent Development Table 83. greenovation Biotech GmbH Company Information Table 84. greenovation Biotech GmbH Business Overview Table 85. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 87. greenovation Biotech GmbH Recent Development Table 88. ChemoCentryx Inc Company Information Table 89. ChemoCentryx Inc Business Overview Table 90. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 92. ChemoCentryx Inc Recent Development Table 93. Alexion Pharmaceuticals Inc Company Information Table 94. Alexion Pharmaceuticals Inc Business Overview Table 95. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 97. Alexion Pharmaceuticals Inc Recent Development Table 98. Akari Therapeutics Plc Company Information Table 99. Akari Therapeutics Plc Business Overview Table 100. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 102. Akari Therapeutics Plc Recent Development Table 103. Achillion Pharmaceuticals Inc Company Information Table 104. Achillion Pharmaceuticals Inc Business Overview Table 105. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 107. Achillion Pharmaceuticals Inc Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Atypical Hemolytic Uremic Syndrome Drug Distributors List Table 111. Atypical Hemolytic Uremic Syndrome Drug Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Atypical Hemolytic Uremic Syndrome Drug Product Image Figure 2. Global Atypical Hemolytic Uremic Syndrome Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Atypical Hemolytic Uremic Syndrome Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Atypical Hemolytic Uremic Syndrome Drug Sales (2021-2032) & (k units) Figure 5. Global Atypical Hemolytic Uremic Syndrome Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Atypical Hemolytic Uremic Syndrome Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. OMS-72 Image Figure 9. Mubodina Image Figure 10. ETR-001 Image Figure 11. ET-006 Image Figure 12. CCX-168 Image Figure 13. ALN-CC5 Image Figure 14. Others Image Figure 15. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2021-2032) Figure 18. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Others Image Figure 24. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2021-2032) Figure 27. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2021-2032) Figure 30. North America Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. North America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 32. U.S. Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. Canada Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Mexico Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 37. Germany Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. France Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. U.K. Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Italy Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Netherlands Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 44. China Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. Japan Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. South Korea Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. Southeast Asia Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. India Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. Australia Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 52. Brazil Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. South Africa Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Saudi Arabia Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Turkey Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. Argentina Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. UAE Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 58. Egypt Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 59. Chile Atypical Hemolytic Uremic Syndrome Drug Sales and Growth Rate (2021-2032) & (k units) Figure 60. Global Atypical Hemolytic Uremic Syndrome Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 63. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 65. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Atypical Hemolytic Uremic Syndrome Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Atypical Hemolytic Uremic Syndrome Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • OMS-72
  • Mubodina
  • ETR-001
  • ET-006
  • CCX-168
  • ALN-CC5
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Amgen Inc
  • Omeros Corp
  • Kedrion SpA
  • greenovation Biotech GmbH
  • ChemoCentryx Inc
  • Alexion Pharmaceuticals Inc
  • Akari Therapeutics Plc
  • Achillion Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Atypical Hemolytic Uremic Syndrome Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Atypical Hemolytic Uremic Syndrome Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Atypical Hemolytic Uremic Syndrome Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Atypical Hemolytic Uremic Syndrome Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Atypical Hemolytic Uremic Syndrome Drug Market Dynamics
  1. 2.1 Atypical Hemolytic Uremic Syndrome Drug Industry Trends
  2. 2.2 Atypical Hemolytic Uremic Syndrome Drug Industry Drivers
  3. 2.3 Atypical Hemolytic Uremic Syndrome Drug Industry Opportunities and Challenges
  4. 2.4 Atypical Hemolytic Uremic Syndrome Drug Industry Restraints
3 Atypical Hemolytic Uremic Syndrome Drug Market by Manufacturers
  1. 3.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Atypical Hemolytic Uremic Syndrome Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Atypical Hemolytic Uremic Syndrome Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Atypical Hemolytic Uremic Syndrome Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers, Product Type & Application
  7. 3.7 Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Atypical Hemolytic Uremic Syndrome Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Atypical Hemolytic Uremic Syndrome Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Atypical Hemolytic Uremic Syndrome Drug Tier 1, Tier 2, and Tier 3
4 Atypical Hemolytic Uremic Syndrome Drug Market by Type
  1. 4.1 Atypical Hemolytic Uremic Syndrome Drug Type Introduction
  2. 4.1.1 OMS-72
  3. 4.1.2 Mubodina
  4. 4.1.3 ETR-001
  5. 4.1.4 ET-006
  6. 4.1.5 CCX-168
  7. 4.1.6 ALN-CC5
  8. 4.1.7 Others
  9. 4.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type
  10. 4.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2032)
  12. 4.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2021-2032)
  13. 4.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type
  14. 4.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2032)
  16. 4.3.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2021-2032)
5 Atypical Hemolytic Uremic Syndrome Drug Market by Application
  1. 5.1 Atypical Hemolytic Uremic Syndrome Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application
  6. 5.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application
  10. 5.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2021-2032)
6 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region
  1. 6.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region
  1. 7.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region
  2. 7.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032)
  8. 7.2.2 North America Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032)
  11. 7.3.2 Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen Inc
  2. 8.1.1 Amgen Inc Company Information
  3. 8.1.2 Amgen Inc Business Overview
  4. 8.1.3 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  6. 8.1.5 Amgen Inc Recent Developments
  7. 8.2 Omeros Corp
  8. 8.2.1 Omeros Corp Company Information
  9. 8.2.2 Omeros Corp Business Overview
  10. 8.2.3 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  12. 8.2.5 Omeros Corp Recent Developments
  13. 8.3 Kedrion SpA
  14. 8.3.1 Kedrion SpA Company Information
  15. 8.3.2 Kedrion SpA Business Overview
  16. 8.3.3 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  18. 8.3.5 Kedrion SpA Recent Developments
  19. 8.4 greenovation Biotech GmbH
  20. 8.4.1 greenovation Biotech GmbH Company Information
  21. 8.4.2 greenovation Biotech GmbH Business Overview
  22. 8.4.3 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  24. 8.4.5 greenovation Biotech GmbH Recent Developments
  25. 8.5 ChemoCentryx Inc
  26. 8.5.1 ChemoCentryx Inc Company Information
  27. 8.5.2 ChemoCentryx Inc Business Overview
  28. 8.5.3 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  30. 8.5.5 ChemoCentryx Inc Recent Developments
  31. 8.6 Alexion Pharmaceuticals Inc
  32. 8.6.1 Alexion Pharmaceuticals Inc Company Information
  33. 8.6.2 Alexion Pharmaceuticals Inc Business Overview
  34. 8.6.3 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  36. 8.6.5 Alexion Pharmaceuticals Inc Recent Developments
  37. 8.7 Akari Therapeutics Plc
  38. 8.7.1 Akari Therapeutics Plc Company Information
  39. 8.7.2 Akari Therapeutics Plc Business Overview
  40. 8.7.3 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  42. 8.7.5 Akari Therapeutics Plc Recent Developments
  43. 8.8 Achillion Pharmaceuticals Inc
  44. 8.8.1 Achillion Pharmaceuticals Inc Company Information
  45. 8.8.2 Achillion Pharmaceuticals Inc Business Overview
  46. 8.8.3 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  48. 8.8.5 Achillion Pharmaceuticals Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Atypical Hemolytic Uremic Syndrome Drug Value Chain Analysis
  2. 9.1.1 Atypical Hemolytic Uremic Syndrome Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Atypical Hemolytic Uremic Syndrome Drug Production Mode & Process
  6. 9.2 Atypical Hemolytic Uremic Syndrome Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Atypical Hemolytic Uremic Syndrome Drug Distributors
  9. 9.2.3 Atypical Hemolytic Uremic Syndrome Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst